RxDoctor Payments Data

Lorin Haynes

Family · Fayetteville, NCNPI 1982234365

Payments from drug & device makers

$3,685in general payments, 2019–2025

Across 182 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Forte Bio-pharma LLC$1K
  • Collegium Pharmaceutical, Inc.$624
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$512
  • Scilex Pharmaceuticals Inc.$290
  • Arbor Pharmaceuticals, Inc.$180
  • Indivior Inc.$151
  • plus $858 from 16 others

What the payments were for

  • Food & beverage$3,685100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,685 in reported general payments places this provider in the 90th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$155,152
Medicare patients
186
Services billed
1,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,539$223,946
Xtampza ErOxycodone Myristate295$196,647
SublocadeBuprenorphine63$127,153
OxycontinOxycodone Hcl160$97,990
ProlateOxycodone Hcl/Acetaminophen22$67,219
RelistorMethylnaltrexone Bromide19$44,823
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl234$37,888
LinzessLinaclotide36$25,584
BelbucaBuprenorphine Hcl40$25,093
NucyntaTapentadol Hcl18$23,960
BrixadiBuprenorphine11$20,271
Hysingla ErHydrocodone Bitartrate27$19,548
BelsomraSuvorexant35$15,064
Piroxicam25$14,249
Diclofenac Sodium92$14,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca, Nucynta$624$245,700353 claims
Indivior Inc.Sublocade$151$127,15363 claims
Forte Bio-pharma LLCProlate$1,070$67,21922 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$512$44,82319 claims
AbbVieLinzess$71$25,58436 claims
Braeburn Inc.Brixadi$117$20,27111 claims
MerckBelsomra$90$15,06435 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,522 family providers in North Carolina.

Other family in Fayetteville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →